Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
about
Early lesions of follicular lymphoma: a genetic perspective.Human Adipose-Derived Mesenchymal Stem Cells in Cell Therapy: Safety and Feasibility in Different "Hospital Exemption" Clinical Applications.Disruption of chromosomal locus 1p36 differentially modulates TAp73 and ΔNp73 expression in follicular lymphoma.Scaffold-free Three-dimensional Graft From Autologous Adipose-derived Stem Cells for Large Bone Defect Reconstruction: Clinical Proof of ConceptPRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.Application of a three-dimensional graft of autologous osteodifferentiated adipose stem cells in patients undergoing minimally invasive transforaminal lumbar interbody fusion: clinical proof of concept.Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients.
P2860
Q35026859-9C45E39E-C3BF-44E9-95B0-0EDD95DF7046Q35814737-ACAC4D09-5BE7-4419-9C22-D48220E758D6Q36351646-35314547-FB60-413C-A9A8-7D4217BA9901Q37328298-5766B928-A246-4B1D-938E-A1309AC4D230Q42623661-62809065-A6C4-4AAD-A5C6-FC606B646388Q49912597-59BFC39B-6783-4ECF-B1B4-173D6CAA67BAQ50980351-5843A764-29B9-4973-AB70-B48456FF4500Q51825432-AC362D4C-4F87-4E05-81F2-DFB36764090E
P2860
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@ast
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@en
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@nl
type
label
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@ast
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@en
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@nl
prefLabel
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@ast
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@en
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@nl
P2093
P2860
P50
P1433
P1476
Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies
@en
P2093
An De Weer
Anabelle Decottignies
Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO)
Christian Herens
Christine Terré
Elise Chapiro
Elise Labis
Eric Lippert
Francine Mugneret
Frédéric Lambert
P2860
P304
P356
10.1371/JOURNAL.PONE.0026311
P407
P50
P577
2011-10-21T00:00:00Z